MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) announced the completion of the acquisition of CN201 from Curon Biopharmaceutical (Curon), a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases. Read more.